Dr Reddy's Laboratories recovers from nine-month low

The stock dipped 7% to Rs 3,138, its lowest level since February 11, 2015 on the National Stock Exchange.

Dr Reddy's Laboratories hits nine month low; dips over 25% in two week
SI Reporter Mumbai
Last Updated : Nov 19 2015 | 1:16 PM IST
Shares of Dr Reddy’s Laboratories trimmed losses and was trading 2% lower after sliding nearly 7% to Rs 3,138, its lowest level since February 11, 2015 on the National Stock Exchange (NSE) in early morning trade.

In the past two weeks, the stock had slipped 26% from Rs 4,253 on November 5, after the company announced that it has received a warning letter from the US Food and Drug Administration ( US FDA) over quality control issues at three of its manufacturing facilities.

Warning letters are issued for violations of regulatory significance and these could lead to enforcement action such as import alerts, if not promptly and adequately corrected in voluntary compliance with the US drug laws by the companies.

Meanwhile, according to media reports, Lundin Law PC said it is investigating claims against Dr. Reddy’s Laboratories concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Dr. Reddy’s were false and misleading concerning the company’s financial performance.

(CLICK HERE TO READ THE FULL REPORT)

Reacting to certain statements that appeared in the media today relating to its corporate governance practices, Dr Reddy’s spokesperson in a press release said that, “Dr. Reddy’s has always adhered to al disclosure requirements both the Securities and Exchange Commission (SECs)  and Indian Stock Exchanges including accounting practices as per the International Financial Reporting Standards (IFRS) and the Indian Accounting Standards.

The company has no further comment on what might be advertorial press releases by law firms and refutes all allegations, it added.

Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking, said ‘currently we don’t think there are any major immediate financial implications of the same and hence, we maintain our numbers and BUY rating with a price target of Rs 3,933.

At 01:05 PM, the stock was down 1.4% at Rs 3,320, recovering nearly 6% from its early morning low on the NSE. The Nifty 50 was up 1.3% or 101 points at 7,833.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 19 2015 | 1:08 PM IST

Next Story